The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Dr Reddy's, Zydus Lifesciences,... Feb 19, 2025 19:23 Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue ...

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

Return on investment - most recent fiscal year 16.16 ...

Mumbai: Cipla Limited has announced that the Company has completed an investment of approx. ZAR 900 million in Cipla Medpro South Africa Proprietary Limited, South Africa, a wholly owned subsidiary in ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

At ₹1,571 crore, Cipla has reported a 49% year-on-year increase in net profits between October and December 2024. The pharma giant’s revenue from operations is ₹7,073 crore, compared to ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...